1-3 of 3
Shannon Marshall
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing

Evgeny Arons, PhD, Daniel Gorelik, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Mark Sokolsky, Hong Zhou, Nai Shun (nancy) Yao, MD, Shannon Marshall, PhD, Katherine Potocka, Erin Fykes, Ira Pastan, MD, Robert J. Kreitman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1861.
https://doi.org/10.1182/blood-2018-99-113419
Published: 2018
Journal Articles

Negative Minimal Residual Disease Associated with Extended Response to Moxetumomab Pasudotox in Patients with Relapsed/Refractory Hairy Cell Leukemia: Long-Term Follow-up of Bone Marrow Immunohistochemistry Analyses from a Phase 1 Study

Robert Kreitman, MD, Martin S. Tallman, MD, Tadeusz Robak, MD PhD, Steven Coutre, MD, Shannon Marshall, PhD, Jie Yang, PhD, Ira Pastan, MD, Nai Shun (Nancy) Yao, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2765.
https://doi.org/10.1182/blood.V130.Suppl_1.2765.2765
Published: 2017
Journal Articles

Sigma 2-Agonist CB-64D Induces Apoptosis in Non Hodgkin’s Lymphoma Cells: Association with Decreased Akt Expression.

Chiara Dell’Agnola, MD, Wojciech Wojciechowski, PhD, Shannon Marshall, Natalia E. Lopez, DDS, Huifen Li, PhD, Wayne D. Bowen, PhD, Igor J. Espinoza-Delgado, MD
Journal: Blood
Blood (2004) 104 (11): 4619.
https://doi.org/10.1182/blood.V104.11.4619.4619
Published: 2004